Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

A total of 64 research findings were accepted, including three Proffered Paper and three Rapid Oral presentations, across more than 10 areas of oncology and supportive care. More than 10 studies were selected to highlight findings on HER2- and HER3-targeted approaches; the excerpt provides no specific results or company attribution.